KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Non Operating Income (2016 - 2025)

Travere Therapeutics' Non Operating Income history spans 13 years, with the latest figure at $11.1 million for Q4 2025.

  • For Q4 2025, Non Operating Income rose 2004.82% year-over-year to $11.1 million; the TTM value through Dec 2025 reached $12.5 million, up 709.51%, while the annual FY2025 figure was $11.6 million, 448.95% up from the prior year.
  • Non Operating Income reached $11.1 million in Q4 2025 per TVTX's latest filing, up from $487000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $11.1 million in Q4 2025 to a low of -$17.2 million in Q4 2021.
  • Average Non Operating Income over 5 years is -$287050.0, with a median of $503500.0 recorded in 2024.
  • The largest YoY upside for Non Operating Income was 3296.15% in 2023 against a maximum downside of 642.32% in 2023.
  • A 5-year view of Non Operating Income shows it stood at -$17.2 million in 2021, then surged by 105.06% to $872000.0 in 2022, then crashed by 642.32% to -$4.7 million in 2023, then surged by 87.71% to -$581000.0 in 2024, then soared by 2004.82% to $11.1 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Non Operating Income are $11.1 million (Q4 2025), $487000.0 (Q3 2025), and -$526000.0 (Q2 2025).